Beyond the blockade: unmet needs in systemic targeted atopic dermatitis therapy.

Front Immunol · 2025 · PMC12695861 · PMID 41394855

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While tezepelumab has shown some efficacy in achieving an EASI-50 response in a phase 2a trial, it did not reach statistical significance for other key disease endpoints ( 43 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.